Tirzepatide vs Semaglutide
Which is more effective for weight loss, Tirzepatide (Mounjaro / Zepbound) or Semaglutide (Ozempic / Wegovy)? Side-by-side on dose, mechanism, side effects, FDA status.
The verdict
Tirzepatide hits two receptors (GLP-1 plus GIP) where Semaglutide hits one, and in head-to-head trials that second lever shows up as more weight lost on average and, for a lot of people, less gut nausea per pound dropped. Semaglutide is the longer-tracked option with the bigger real-world history, so it's the more conservative starting point. If you're picking fresh and want the stronger effect, Tirzepatide is the one most people reach for now; if you value the longer track record, Semaglutide still earns its place.
Tirzepatide is the prescription weight-loss drug sold as Mounjaro (diabetes) or Zepbound (weight loss). It hits two appetite-control receptors at once. Most users lose 15-20% of body weight over several months. One injection per week.
Semaglutide is the first wave of modern weight-loss drugs, sold as Ozempic and Wegovy. Single-receptor version of Tirzepatide. Slightly less effective and slightly rougher side effects, but well-studied and widely available.
Which one should you pick?
Pick Tirzepatide if users who couldn't tolerate semaglutide or metabolic-syndrome adults under provider guidance.
Pick Semaglutide if beginners to glp-class peptides or users with insurance coverage on wegovy / ozempic.
Still torn between Tirzepatide and Semaglutide?
The AI Coach reads both, asks about your goal and experience, and tells you which one actually fits — plus how to dose and stack it. Free.